Medivir AB (STU:MVR0) Cyclically Adjusted Book per Share: €0.97 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:MVR0 Medivir AB STU:MVR0
52 GF Score
Price €0.14
GF Value €0.10
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medivir AB Cyclically Adjusted Book per Share?

Medivir AB STU:MVR0 -2.47% 52 Cyclically Adjusted Book per Share is €0.97 as of Jun. 2026. GuruFocus rates STU:MVR0 with a GF Score™ of 52/100 and a GF Value™ of €0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Medivir AB's adjusted book value per share for the three months ended in Jun. 2026 was €0.043. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.97 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Medivir AB's average Cyclically Adjusted Book Growth Rate was -32.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -18.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Medivir AB was 0.10% per year. The lowest was -18.90% per year. And the median was -3.10% per year.

As of today (2026-09-19), Medivir AB's current stock price is €0.1422. Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €0.97. Medivir AB's Cyclically Adjusted PB Ratio of today is 0.15.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medivir AB was 2.89. The lowest was 0.03. And the median was 0.31.


Medivir AB  (STU:MVR0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medivir AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.1422/0.966
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medivir AB was 2.89. The lowest was 0.03. And the median was 0.31.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Medivir AB Cyclically Adjusted Book per Share Related Terms


Medivir AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Medivir AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Cyclically Adjusted Book per Share Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.34 2.37 2.22 1.65 1.13

Medivir AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.47 1.33 1.20 1.08 0.97

STU:MVR0 vs VRTX, REGN, MRNA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PB Ratio falls into.


STU:MVR0
52GF Score
Medivir AB STU:MVR0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medivir AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.043/134.6100*134.6100
=0.043

Current CPI (Jun. 2026) = 134.6100.

Medivir AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.423 101.138 4.556
201612 4.520 102.022 5.964
201703 2.743 102.022 3.619
201706 2.406 102.752 3.152
201709 2.118 103.279 2.761
201712 1.732 103.793 2.246
201803 1.577 103.962 2.042
201806 1.309 104.875 1.680
201809 1.132 105.679 1.442
201812 0.841 105.912 1.069
201903 0.670 105.886 0.852
201906 0.628 106.742 0.792
201909 0.560 107.214 0.703
201912 0.487 107.766 0.608
202003 0.411 106.563 0.519
202006 0.393 107.498 0.492
202009 0.404 107.635 0.505
202012 0.391 108.296 0.486
202103 0.481 108.360 0.598
202106 0.461 108.928 0.570
202109 0.442 110.338 0.539
202112 0.401 112.486 0.480
202203 0.352 114.825 0.413
202206 0.309 118.384 0.351
202209 0.285 122.296 0.314
202212 0.255 126.365 0.272
202303 0.227 127.042 0.241
202306 0.181 129.407 0.188
202309 0.156 130.224 0.161
202312 0.187 131.912 0.191
202403 0.162 132.205 0.165
202406 0.135 132.716 0.137
202409 0.112 132.304 0.114
202412 0.090 132.987 0.091
202503 0.084 132.825 0.085
202506 0.063 133.699 0.063
202509 0.053 133.480 0.053
202512 0.032 133.380 0.032
202603 0.032 133.550 0.032
202606 0.043 134.610 0.043

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.97 mean?
Medivir AB (STU:MVR0) has a Cyclically Adjusted Book per Share of €0.97 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medivir AB and its competitors.
Is Medivir AB's Cyclically Adjusted Book per Share too high?
Medivir AB's current Cyclically Adjusted Book per Share is €0.97. Overall, Medivir AB has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Medivir AB's Cyclically Adjusted Book per Share of €0.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medivir AB and its competitors. Medivir AB's current Cyclically Adjusted Book per Share is €0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (STU:MVR0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.10, compared to a current price of €0.14 — trading 42.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is €0.97. Medivir AB's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Medivir AB (STU:MVR0), the current Cyclically Adjusted Book per Share is €0.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (STU:MVR0) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of €0.14 is trading 42.2% above its estimated GF Value™ of €0.10. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for STU:MVR0:

  • Cyclically Adjusted Book per Share: €0.97
  • GF Value™: €0.10 vs. price of €0.14 (42.2% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the STU:MVR0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Other Exchanges MVIR:SwedenMVIRs:UK0GP7:UK
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
52GF Score

Get the complete analysis for STU:MVR0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.10
GF Value